


Selurampanel

Chemical Properties

CAS No. :	912574-69-7
Formula:	C ₁₆ H ₁₉ N ₅ O ₄ S
Molecular Weight:	377.42
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Selurampanel (BGG492) is an orally active and selective competitive AMPA glutamate receptor antagonist, a quinazoline-dione sulfonamide. selurampanel is used in the study of epilepsy, migraine and tinnitus.
Targets(IC50)	iGluR
In vivo	Selurampanel (3 mg/kg i.v.) a mouse plasma half-life of 3.3 h is determined, with a moderate volume of distribution (V _{dss} =1.3 L/kg) and a low clearance of 5.4 mL/minkg. [5] Selurampanel potently and dose-dependently antagonizes maximal electroshock seizure-induced generalized tonic-clonic seizures in mice with an ED ₅₀ value around 7 mg/kg after 1 h pre-treatment.[5]

Solubility Information

Solubility	DMSO: 27.5 mg/mL (72.86 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6496 mL	13.2478 mL	26.4957 mL
5 mM	0.5299 mL	2.6496 mL	5.2991 mL
10 mM	0.265 mL	1.3248 mL	2.6496 mL
50 mM	0.053 mL	0.265 mL	0.5299 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Zaccara G, et al. Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development. *Pharmacol Res.* 2015 ; 104: 38-48.

Kasteleijn-Nolst Trenité D, et al. Dose-dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship. *Epilepsia.* 2015 ; 56(6):924-32.

Faught E. BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy. *Expert Opin Investig Drugs.* 2014 ; 23(1):107-113.

Gomez-Mancilla B, et al. BGG492 Study Group. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. *Cephalalgia.* 2014 ; 34(2):103-113.

Orain D, et al. Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist. *ChemMedChem.* 2017 ; 12(3):197-201.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481